|
CN103038235B
(zh)
*
|
2010-06-01 |
2015-07-29 |
拜耳知识产权有限责任公司 |
取代的咪唑并吡嗪
|
|
MX380504B
(es)
|
2010-06-03 |
2025-03-12 |
Pharmacyclics Llc |
El uso de inhibidores de la tirosina quinasa de bruton (btk).
|
|
WO2012170827A2
(en)
*
|
2011-06-08 |
2012-12-13 |
Cylene Pharmaceuticals, Inc. |
Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
|
|
WO2012178125A1
(en)
|
2011-06-22 |
2012-12-27 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
IN2014DN09528A
(enExample)
*
|
2012-04-27 |
2015-07-17 |
Nippon Steel & Sumitomo Metal Corp |
|
|
US20150182490A1
(en)
|
2012-06-26 |
2015-07-02 |
Del Mar Pharmaceuticals |
Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
|
|
TW201414737A
(zh)
*
|
2012-07-13 |
2014-04-16 |
必治妥美雅史谷比公司 |
作爲激酶抑制劑之咪唑并三□甲腈
|
|
HK1206073A1
(en)
|
2012-07-24 |
2015-12-31 |
药品循环有限责任公司 |
Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
|
|
LT3418281T
(lt)
|
2012-12-07 |
2021-01-11 |
Vertex Pharmaceuticals Inc. |
Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
|
|
EP2943485B1
(en)
|
2013-01-14 |
2017-09-20 |
Incyte Holdings Corporation |
Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
|
|
TWI662030B
(zh)
|
2013-01-15 |
2019-06-11 |
英塞特控股公司 |
適用作ｐｉｍ激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物
|
|
WO2014143240A1
(en)
|
2013-03-15 |
2014-09-18 |
Vertex Pharmaceuticals Incorporated |
Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
|
|
EP2970288A1
(en)
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
EP2970289A1
(en)
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
|
CN105492011A
(zh)
|
2013-04-08 |
2016-04-13 |
丹尼斯·M·布朗 |
不理想给药化学化合物的治疗增效
|
|
CN103360399B
(zh)
*
|
2013-08-02 |
2016-03-02 |
北京大学 |
6-芳基取代-咪唑-[1,2-b]哒嗪类衍生物，其制备方法及用途
|
|
US9556197B2
(en)
|
2013-08-23 |
2017-01-31 |
Incyte Corporation |
Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
|
|
CN103570728B
(zh)
*
|
2013-11-12 |
2015-12-30 |
山东大学 |
一种取代吡唑并[1,5-a]嘧啶类衍生物及其制备方法与应用
|
|
HUE046727T2
(hu)
|
2013-12-06 |
2020-03-30 |
Vertex Pharma |
Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
|
|
ES2702126T3
(es)
*
|
2013-12-10 |
2019-02-27 |
Bristol Myers Squibb Co |
Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
|
|
TWI534148B
(zh)
*
|
2014-02-13 |
2016-05-21 |
生華生物科技股份有限公司 |
吡唑並嘧啶前藥及其使用方法
|
|
GB201403093D0
(en)
*
|
2014-02-21 |
2014-04-09 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
JP6545197B2
(ja)
*
|
2014-05-28 |
2019-07-17 |
ノバルティス アーゲー |
新規なピラゾロピリミジン誘導体およびｍａｌｔ１阻害剤としてのその使用
|
|
ES2777608T3
(es)
|
2014-06-05 |
2020-08-05 |
Vertex Pharma |
Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
|
|
US11179394B2
(en)
|
2014-06-17 |
2021-11-23 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of Chk1 and ATR inhibitors
|
|
US9580418B2
(en)
|
2014-07-14 |
2017-02-28 |
Incyte Corporation |
Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
|
|
WO2016010897A1
(en)
|
2014-07-14 |
2016-01-21 |
Incyte Corporation |
Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
|
|
CN105457029A
(zh)
*
|
2014-09-29 |
2016-04-06 |
中国科学院上海巴斯德研究所 |
抑制酪蛋白激酶2活性在促进i型干扰素表达的应用
|
|
CA2968884A1
(en)
*
|
2014-12-10 |
2016-06-16 |
Massachusetts Institute Of Technology |
Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
|
|
ES2754803T3
(es)
*
|
2015-01-23 |
2020-04-20 |
Glaxosmithkline Ip Dev Ltd |
Derivado de pirazolo[3,4-dpirimidina y su uso para el tratamiento de leishmaniasis
|
|
WO2016196244A1
(en)
|
2015-05-29 |
2016-12-08 |
Incyte Corporation |
Pyridineamine compounds useful as pim kinase inhibitors
|
|
AR105967A1
(es)
|
2015-09-09 |
2017-11-29 |
Incyte Corp |
Sales de un inhibidor de pim quinasa
|
|
US11464774B2
(en)
|
2015-09-30 |
2022-10-11 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
|
|
WO2017059251A1
(en)
|
2015-10-02 |
2017-04-06 |
Incyte Corporation |
Heterocyclic compounds useful as pim kinase inhibitors
|
|
RU2018132559A
(ru)
|
2016-02-16 |
2020-03-17 |
Массачусетс Инститьют Оф Текнолоджи |
Связывающие молекулы для max в качестве модуляторов myc и их применения
|
|
CA3028727A1
(en)
*
|
2016-06-24 |
2017-12-28 |
Polaris Pharmaceuticals, Inc. |
Ck2 inhibitors, compositions and methods thereof
|
|
MX2019012431A
(es)
|
2017-04-21 |
2020-08-03 |
Ikena Oncology Inc |
Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
|
|
CN107188901A
(zh)
*
|
2017-05-27 |
2017-09-22 |
无锡捷化医药科技有限公司 |
一种(3‑(3‑(二甲氨基)丙氧基)苯基)硼酸的制备方法
|
|
ES2962961T3
(es)
|
2017-07-28 |
2024-03-22 |
Yuhan Corp |
Procedimiento de preparación de n-(5-((4-(4-(dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamida haciendo reaccionar la amina correspondiente con un cloruro de 3-halo-propionilo
|
|
IL317854A
(en)
|
2017-07-28 |
2025-02-01 |
Takeda Pharmaceuticals Co |
TYK2 inhibitors and their uses
|
|
GB201715194D0
(en)
|
2017-09-20 |
2017-11-01 |
Carrick Therapeutics Ltd |
Compounds and their therapeutic use
|
|
TW201924683A
(zh)
|
2017-12-08 |
2019-07-01 |
美商英塞特公司 |
用於治療骨髓增生性贅瘤的低劑量組合療法
|
|
US11071727B2
(en)
|
2018-01-26 |
2021-07-27 |
Northwestern University |
Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
|
|
KR20250174699A
(ko)
|
2018-10-30 |
2025-12-12 |
크로노스 바이오, 인코포레이티드 |
Cdk9 활성을 조절하기 위한 화합물, 조성물 및 방법
|
|
CN112608316B
(zh)
*
|
2019-07-30 |
2022-10-21 |
厦门宝太生物科技股份有限公司 |
一种吡唑并三嗪类腺苷受体拮抗剂
|
|
AU2020394424A1
(en)
|
2019-11-26 |
2022-06-16 |
Ikena Oncology, Inc. |
Polymorphic carbazole derivatives and uses thereof
|
|
GB201918541D0
(en)
|
2019-12-16 |
2020-01-29 |
Carrick Therapeutics Ltd |
Therapeutic compounds and their use
|
|
KR102337404B1
(ko)
*
|
2020-01-03 |
2021-12-10 |
연세대학교 산학협력단 |
조직 재생용 조성물
|
|
JP2023520882A
(ja)
*
|
2020-03-30 |
2023-05-22 |
センホア・バイオサイエンシーズ・インコーポレイテッド |
肝臓指向性のウイルス感染症、特にｂ型肝炎およびｄ型肝炎を処置するための抗ウイルス化合物および方法
|
|
KR20230069126A
(ko)
*
|
2020-09-15 |
2023-05-18 |
미쓰비시 타나베 파마 코퍼레이션 |
트리아진 화합물의 염, 그 결정형 및 제조 방법
|
|
EP4121431A1
(en)
*
|
2021-01-09 |
2023-01-25 |
Bugworks Research, Inc. |
Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2a receptor and adenosine 2b receptor antagonist
|
|
US12343421B2
(en)
*
|
2021-11-01 |
2025-07-01 |
Solaana MD LLC |
Vitamin D base layer
|
|
EP4676476A1
(en)
*
|
2023-03-09 |
2026-01-14 |
Aquinnah Pharmaceuticals, Inc. |
Inhibitors of tdp-43 and tau aggregation
|
|
US12269826B1
(en)
*
|
2023-11-16 |
2025-04-08 |
King Faisal University |
7H-pyrido[4′,3′:4,5]pyrrolo[2,3-c][1,7]naphthyridine compounds as CK2 inhibitors
|